Foundation / Corporation
Israel Cancer Research Fund (ICRF)
01/17/18 11:59 PM ET Receipt
Grants of up to $45,000 per year to Israel early-career medical researchers employed by public or private nonprofit research institutions for clinical cancer research. The purpose of this program is to enhance the research capabilities of young Israeli scientists who are in a formative career phase, and who have shown outstanding potential for contribution to clinical cancer research as independent investigators.
The awards are available for persons with research potential who need additional experience in a scientific environment that is conducive to the development of a career in clinical research. The award is not intended for those already established as independent investigators. The award is not intended simply to substitute one source of salary support for another for an individual who is already conducting full-time research, nor is it a mechanism for providing institutional support. Its main purpose is to provide free time for a young medical or pediatric oncologist to devote to a clinical research project conducted in Israel and to obtain additional (post-fellowship) training to become a leader in clinical research programs.
Because this funding opportunity targets development of early career investigators, it is important, and requisite, that a formal mentoring program be established for the investigator. There should be a primary mentor who should be available for guidance at all times. It is preferable that the primary mentor be at the same institution as the investigator. In addition, there should be a small mentoring committee formed of additional senior members who will meet with the investigators quarterly to evaluate progress and give guidance. All CRCDA applications must include letters of support from the primary mentor and members of the mentoring committee.
Definitions of Research Areas:
Clinical Research utilizes human subjects or materials and has direct application to the prevention, diagnosis, or treatment of cancer in the individual or group of individuals under study, or the rehabilitation (including quality of life issues) of the patient. Clinical Research also includes:
1. Cancer Control Research - Investigates how scientifically obtained information on prevention, early detection, early diagnosis, state-of-the-art treatment, or rehabilitation can be efficiently and effectively applied to defined groups of people or at the community level to reduce the burden of cancer.
2. Health Service Research - Also called research on access to care, this research deals with the ways by which people interface with health care delivery systems. It investigates the barriers to health care and the differing, and often changing, needs of patients.
3. Psychosocial and Behavioral Cancer Research - Directed at understanding and improving the motivational factors in cancer prevention and screening, and the social and emotional impact of cancer and its treatment on individuals, their families, and their caregivers.
4. Cancer Genetics and Genetic Counseling Research.
5. Translational Research – Collaboration between basic and clinical scientists with the intent of enhancing the transfer of basic research findings to clinical usefulness.
Scientific Review of Applications:
Applications will be considered for funding on the basis of the overall merit of the proposal as determined by the Scientific Review Panel, relevance of the proposal to the objectives of the ICRF, and the availability of funds. The proposal must be a clinical trial and may involve multiple institutions provided that the intent to collaborate is documented.
In the review of applications for scientific merit, attention is given to the candidate's prior training and experience, career potential, proposed research, environment, and other related information. The application must demonstrate that the award will enhance the candidate's development as an independent clinical investigator. The relationship of the research to cancer must be defined in the application.
Commitment to Research:
Individuals who receive a CRCDA are to devote at least half of their time to clinical research activities. Such activities may include giving or receiving research training, supervising the research of others, and participating in workshops and scientific or professional meetings. The principal involvement must be with the actual conduct of research. It is expected that the other portion of the awardee's time will be devoted to direct patient care at the funded institution.
During the period of the award, the institution is expected to reduce or defer demands for teaching, service or committee duties that do not contribute directly to the development of the candidate's research career.
Allowable Award Costs
The CRCDA will reimburse the grantee institution for the employee's research and training efforts which must encompass at least 50% of his or her time at the institution. The CRCDA may be used for any combination of salary and research costs incurred by the awardee, including attendance at cooperative cancer treatment group meetings and expenses for training in clinical research methodology and biostatistics.
The total salary of the investigator (ICRF and institutional contribution) must be based on a full-time, 12-month staff appointment, and be consistent with both the established salary structure at the institution and with salaries provided by the institution to other staff members of equivalent qualifications, rank and responsibilities in the department concerned. If full-time salaries are not currently paid to comparable staff members, the salary proposed must be appropriately related to the existing part-time salary structure.
The CRCDA is made with the expectation that additional research support and salary funds from the institution will be available to the awardee during the period of the award, and that full-time employment of the awardee will be assured for a minimum of 3 years after completion of the CRCDA, with appropriate funding for continued clinical research activities.
Type of Clinical Trials to be Supported:
Phase I (tolerance and toxicity) trials may be performed under a CRCDA proposal provided that an experienced clinical investigator (mentor) provides assurance of appropriate supervision. Phase II and Phase III trials may be proposed for support of this type, and may involve more than one institution provided that the appropriate consortium agreements are obtained.
Pharmaceutical Industry Involvement:
Financial support and proprietary drug provision are permitted, provided that a letter from the manufacturer or supplier clearly indicates they will have no control or influence over publication or dissemination of results of the project.
The funds are to be used for actual direct expenses (salary, supplies, tuition, seminar registration, meeting attendance, etc.) connected with the project.
GrantWatch ID#: 164775
Support is limited to a maximum of $45,000 per year.
Awards will be activated September 1, 2018.
CRCDAs are awarded, contingent upon the availability of funds, for a single support period of three (3) years.
Funds for cancer research are available to citizens of Israel, both native-born and those who have settled. Funds are not available to visiting scientists. (Proof of Israeli citizenship must be furnished upon request.)
Although individuals are considered as the awardee, awards are made to eligible institutions on behalf of the awardee. The awardee is an employee of the institution to which the award is made and his or her status, title, salary and staff privileges are determined by the institution according to its established policies for individuals holding 12-month appointments, except as otherwise set out in this statement.
1. Nomination and Commitment by Institution
Candidates must be nominated by a public or private nonprofit institution engaged in healthcare and healthcare-related research and located in Israel. The application must originate jointly with the institution and the proposed nominee, and must describe fully all proposed research, teaching, and medical activities. The endorsement (signature) of the head of the institution or other person authorized to commit the institution to abide by the requirements of the ICRF is required. A letter from the Dean, relevant Department Chair, or other appropriate senior hospital/university official should accompany the application detailing the institutional support available to the applicant during the period of the award, as well as its future plans for the applicant after completion of the award term.
Candidates must have a medical degree and at least two years of fellowship training in medical or pediatric hematology-oncology or a related oncologic specialty, but not more than five years of subsequent relevant professional experience prior to the requested beginning date of the award.
3. Concurrent Awards
A CRCDA applicant may not accept another clinical research career development type of award that would duplicate the provisions of the ICRF grant. Other development awards considered to be duplicative include clinical investigator awards, academic and teacher investigator awards, and postdoctoral and senior fellowships.
Past recipients are not permitted to reapply for this award.
No overhead, clerical or other administrative charges can be made by the institution against the award funds. The ICRF also does not allow its funds to be used for work performed outside of Israel. However, travel expenses of up to a maximum of $1,000 may be budgeted for RCDAs, CRCDAs, and Postdoctoral Fellowships only.
The application deadline is January 17, 2018, at 11:59 PM ET.
-Application Received by the Fund in New York: January 17, 2018
-Notification of Decision: July 1, 2018
-Activation of Award: September 1, 2018
Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.
Register to apply:
Ellen T. Rubin, Director, Research Grants
Israel Cancer Research Fund
52 Vanderbilt Avenue, Suite 1510
New York, NY 10017-3834